Nektar Therapeutics beat its Q3 earnings estimates, which is generally a positive signal. However, the company's share price dropped by 8.94% the day after the last quarter's earnings beat, indicating that investors may have reacted negatively to other aspects of the earnings report. This pattern could potentially repeat itself.